| Molecular formula | C47H58N12O6 |
|---|
| Molecular weight | 887 g/mol |
|---|
| Registered trials | 0 |
|---|
| PubChem CID | 6918297 |
|---|
What hexarelin is
Hexarelin is a synthetic peptide studied in laboratory and early clinical research settings. It has no FDA-approved label, no approved brand name, and no authorized medical use in the United States. Its molecular formula is C47H58N12O6, with a molecular weight of about 887 (PubChem CID 6918297).
Regulatory and research status
Hexarelin is classified as an unapproved research compound. It is not reviewed or approved by the FDA for any indication, and no prescribing label exists for it.
Trial footprint
Public trial registries currently list no registered clinical trials for hexarelin. This means there is no available sample of study titles, phases, or statuses to summarize at this time.
FAQ
No. Hexarelin has no FDA-approved label, no approved brand name, and no authorized medical use. It is classified as an unapproved research compound.
Hexarelin is a synthetic peptide with the molecular formula C47H58N12O6 and a molecular weight of approximately 887. It is cataloged in PubChem under CID 6918297.
Public trial registries currently show no registered clinical trials for hexarelin. As a result, no phase, status, or study details are available to report.
No adverse event report data is currently available for hexarelin in the reviewed sources. Without an approved label or trial data, no safety profile can be summarized.
No. Because hexarelin lacks FDA approval and an official label, it has no established medical use. Any use outside of formal research settings falls outside its unapproved research status.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: PubChem ClinicalTrials.gov
Updated 2026-08-03